Vimarsana
Biggest News Aggregation in the World

Page 36 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody - Vimarsana News

Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization

Junshi Biosciences Announces Acceptance by NMPA of - Vimarsana News

Junshi Biosciences Announces Acceptance by NMPA of

SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

Junshi Biosciences: Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer - Vimarsana News

Junshi Biosciences: Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone - - Data support the use of toripalimab with chemotherapy as first-line

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon to Carry Out Development Projects in Omsk - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon to Carry Out Development Projects in Omsk

Investegate announcements from Etalon Group PLC, Etalon to Carry Out Development Projects in Omsk